The World of Clinical Trial Development Post-Covid-19: Lessons Learned from a Global Pandemic.
Ce dossier présente un ensemble d'articles concernant la prise en charge des cancers durant la crise sanitaire liée au COVID-19
The novel coronavirus disease-2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), is a global health threat.Cancer patients are one of the most vulnerable populations. During this pandemic clinical trial accrual to NCI studies has fallen dramatically. Investigators quickly turned to regulatory bodies to simplify treatment schedules, facilitate telemedicine and to decrease required data collection Going forward the oncology research community must use the lessons learned to focus on redesigning studies to ensure that the critical scientific questions are answered safely while expanding access and increasing partnerships with community physicians. These changes will accelerate clinical progress while protecting our patients.
Clinical Cancer Research , résumé, 2019